NKTR vs. OMER, ASMB, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, and ZTS
Should you be buying Nektar Therapeutics stock or one of its competitors? The main competitors of Nektar Therapeutics include Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), and Zoetis (ZTS). These companies are all part of the "pharmaceuticals" industry.
Nektar Therapeutics vs.
Omeros (NASDAQ:OMER) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, community ranking, media sentiment, profitability, analyst recommendations, risk and valuation.
Omeros currently has a consensus price target of $22.50, suggesting a potential upside of 145.10%. Nektar Therapeutics has a consensus price target of $4.08, suggesting a potential upside of 338.03%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nektar Therapeutics is more favorable than Omeros.
48.8% of Omeros shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 12.3% of Omeros shares are owned by insiders. Comparatively, 3.7% of Nektar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -180.70%. Omeros' return on equity of 0.00% beat Nektar Therapeutics' return on equity.
Omeros received 112 more outperform votes than Nektar Therapeutics when rated by MarketBeat users. Likewise, 71.05% of users gave Omeros an outperform vote while only 70.84% of users gave Nektar Therapeutics an outperform vote.
Omeros has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.
Omeros has higher earnings, but lower revenue than Nektar Therapeutics. Omeros is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Omeros and Omeros both had 6 articles in the media. Nektar Therapeutics' average media sentiment score of 0.64 beat Omeros' score of 0.29 indicating that Nektar Therapeutics is being referred to more favorably in the news media.
Summary
Nektar Therapeutics beats Omeros on 9 of the 16 factors compared between the two stocks.
Get Nektar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nektar Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NKTR) was last updated on 2/21/2025 by MarketBeat.com Staff
